I’m the first person whose life was saved by CRISPR base editing
When standard leukaemia treatments failed, 13-year-old Alyssa Tapley was told she had only weeks left – but then she was offered an experimental procedure
When standard leukaemia treatments failed, 13-year-old Alyssa Tapley was told she had only weeks left – but then she was offered an experimental proce
Read Full Story at New Scientist →Why This Matters
The emergence of CRISPR base editing as a viable medical intervention marks a turning point in precision medicine, proving that gene-editing tools can transition from theoretical breakthroughs to life-saving therapies. Alyssa Tapley’s case could accelerate regulatory approvals and insurance coverage for similar treatments, normalizing genomic interventions as frontline options rather than last resorts.
Background Context
CRISPR’s evolution from a bacterial immune system to a gene-editing tool has been rapid but uneven, with early successes primarily in inherited blood disorders like sickle cell disease. Regulatory agencies have historically treated gene therapies as high-risk biologics, delaying access even as academic labs and biotech firms race to refine the technology. The fact that base editing avoids some risks of traditional CRISPR—like unintended DNA breaks—adds urgency to this moment.
What Happens Next
This trial’s outcomes will shape future trials, with scientists closely monitoring whether Alyssa’s immune system tolerates the edited cells long-term or if resistance develops. If successful, pharmaceutical giants could pivot from developing drugs to engineering cures, redefining the economics of oncology. Meanwhile, ethical debates will intensify over who gets access first—rich nations or global patients—and whether gene edits should be reversible.
Bigger Picture
CRISPR’s progress is part of a broader shift toward biologics over small-molecule drugs, with gene therapies increasingly seen as the next pharmaceutical revolution. The success of base editing could also reignite investment in antisense therapies and other RNA-targeting technologies, blurring the lines between genetic and epigenetic medicine. Politically, this moment may force governments to confront the inadequacy of current healthcare systems to handle one-time, high-cost interventions.
